Targeting a protein complex to treat triple negative breast cancer
Small molecules targeting RuvBL complex for triple negative breast cancer
['FUNDING_R01'] · OREGON HEALTH & SCIENCE UNIVERSITY · NIH-10865018
This study is working on new treatments for triple negative breast cancer by creating small molecules that can block a key complex involved in repairing DNA damage, which could help kill cancer cells while leaving healthy cells unharmed.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | OREGON HEALTH & SCIENCE UNIVERSITY (nih funded) |
| Locations | 1 site (PORTLAND, UNITED STATES) |
| Trial ID | NIH-10865018 on ClinicalTrials.gov |
What this research studies
This research focuses on developing small molecules that can inhibit the RuvBL1/L2 complex, which plays a crucial role in repairing DNA damage in triple negative breast cancer (TNBC) cells. By targeting the DNA double-strand breaks that are prevalent in TNBC, the research aims to create therapies that selectively kill cancer cells while sparing normal cells. The project will explore the mechanism of action of these compounds and optimize their effectiveness as potential treatments for TNBC. Patients may benefit from new therapeutic options that specifically address the unique vulnerabilities of their cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with triple negative breast cancer who may benefit from novel treatment options.
Not a fit: Patients with other types of breast cancer or those whose cancer is not triple negative may not receive benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to new targeted therapies for patients with triple negative breast cancer, improving treatment outcomes.
How similar studies have performed: Other research has shown promise in targeting DNA repair mechanisms in cancer, suggesting that this approach could be effective.
Where this research is happening
PORTLAND, UNITED STATES
- OREGON HEALTH & SCIENCE UNIVERSITY — PORTLAND, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: XIAO, XIANGSHU — OREGON HEALTH & SCIENCE UNIVERSITY
- Study coordinator: XIAO, XIANGSHU
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.